Blitz Bureau
New Delhi: The Indian pharma and healthcare sector witnessed significant activity in the April-June quarter (Q2) this year with 55 deals totalling $4.1 billion, marking an 8 times increase in values over the previous quarter, according to a report.
The average deal size surged from $9.7 million in Q1 2024 to $74 million this quarter, driven by 11 high-value deals worth $3.4 billion, compared to just one high-value deal worth $150 million in Q1 2024, according to the report by Grant Thornton Bharat.
“As India strives towards Viksit Bharat, we anticipate a substantial rise in the health budget to approximately 3 per cent of GDP in the upcoming Union Budget 2024,” said Bhanu Prakash Kalmath SJ, Partner and Healthcare Services Industry Leader. Compared to Q2 2023, deal values increased by 57 per cent despite a notable $2 billion deal in the previous year executed by Temasek Holdings to acquire a 41 per cent stake in Manipal Health Enterprises.
The largest PE deal was KKR Asian Fund IV’s investment in Healthium MedTech, valued at $843 million, accounting for 31 per cent of the quarter’s PE values.
